Senior Leadership

Keith Hornberger, Ph.D.

Vice President of Discovery Chemistry

Dr. Keith Hornberger is Vice President of Discovery Chemistry at Arvinas, where he leads the medicinal chemistry, platform chemistry, and computational chemistry functions supporting the discovery of PROTAC® targeted protein degraders. Dr. Hornberger joined Arvinas in 2016 and brings over 20 years of experience in the pharmaceutical industry.

Prior to joining Arvinas, Dr. Hornberger previously held multiple positions of increasing responsibility in preclinical drug discovery at GlaxoSmithKline, OSI Pharmaceuticals (a subsidiary of Astellas Pharma), and Boehringer Ingelheim. During this time, he was involved in the advancement of multiple assets in oncology, immunology, and cardiometabolic disease into clinical trials, including the marketed BRAF inhibitor Tafinlar® (dabrafenib) for metastatic melanoma.

Dr. Hornberger completed his undergraduate degree in Chemistry at the University of Delaware, and his Ph.D. in Chemistry at Columbia University.